Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585650 · ClinicalTrials.gov registry record · Phase 1
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
A Phase 1 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00585650 is a Phase 1 study that has completed, run by University of California, Irvine. The registered enrollment target is 20 participants.
The verdict
NCT00585650, a Phase 1 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to see how well (compared to placebo) Enbrel® (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or feet (palmoplantar psoriasis).
Interventions
- BIOLOGICAL Etanercept
- OTHER Placebo injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585650
The ClinicalTrials.gov registry entry for NCT00585650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etanercept is the first listed.
NCT00585650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585650 about?
NCT00585650 is a clinical study titled "Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet". The purpose of this research study is to see how well (compared to placebo) Enbrel® (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or feet (palmoplantar psoriasis).
What is the current status of trial NCT00585650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00585650?
The interventions under investigation include: Etanercept (BIOLOGICAL), Placebo injections (OTHER).
Who is sponsoring clinical trial NCT00585650?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.